Literature DB >> 22474673

Value of the hemorrhage exclusion sign on T1-weighted prostate MR images for the detection of prostate cancer.

Tristan Barrett1, Hebert Alberto Vargas, Oguz Akin, Debra A Goldman, Hedvig Hricak.   

Abstract

PURPOSE: To retrospectively determine the prevalence and positive predictive value (PPV) of the hemorrhage exclusion sign on T1-weighted magnetic resonance (MR) images in conjunction with findings on T2-weighted images in the detection of prostate cancer, with use of whole-mount step-section pathologic specimens from prostatectomy as the reference standard.
MATERIALS AND METHODS: The institutional review board approved this retrospective study, which was compliant with HIPAA, and the requirement to obtain informed consent was waived. Two hundred ninety-two patients with biopsy-proved prostate cancer underwent endorectal MR imaging followed by prostatectomy. The hemorrhage exclusion sign was defined as the presence of a well-defined area of low signal intensity surrounded by areas of high signal intensity on T1-weighted images. Two readers independently assessed the presence and extent of postbiopsy changes and the hemorrhage exclusion sign. The presence of a corresponding area of homogeneous low signal intensity on T2-weighted images was also recorded. The prevalence and PPV of the hemorrhage exclusion sign were calculated.
RESULTS: Readers 1 and 2 found postbiopsy changes in the peripheral zone in 184 (63%) and 189 (64.7%) of the 292 patients, respectively. In these patients, the hemorrhage exclusion sign was observed in 39 of 184 patients (21.2%) by reader 1 and 36 of 189 patients (19.0%) by reader 2. A corresponding area of homogeneous low signal intensity was seen on T2-weighted images in the same location as the hemorrhage exclusion sign in 23 of 39 patients (59%) by reader 1 and 19 of 36 patients (53%) by reader 2. The PPV of the hemorrhage exclusion sign alone was 56% (22 of 39 patients) for reader 1 and 50% (18 of 36 patients) for reader 2 but increased to 96% (22 of 23 patients) and 95% (18 of 19 patients) when the sign was identified in an area of homogeneous low signal intensity on T2-weighted images.
CONCLUSION: Postbiopsy change is a known pitfall in the interpretation of T2-weighted images. The authors have shown that a potential benefit of postbiopsy change is the presence of excluded hemorrhage, which, in conjunction with a corresponding area of homogeneous low signal intensity at T2-weighted imaging, is highly accurate for cancer identification.

Entities:  

Mesh:

Year:  2012        PMID: 22474673      PMCID: PMC3359512          DOI: 10.1148/radiol.12112100

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  14 in total

1.  Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging.

Authors:  Aliya Qayyum; Fergus V Coakley; Ying Lu; Jeffrey D Olpin; Louis Wu; Benjamin M Yeh; Peter R Carroll; John Kurhanewicz
Journal:  AJR Am J Roentgenol       Date:  2004-10       Impact factor: 3.959

2.  Nodular hyperplasia in the peripheral zone of the prostate gland.

Authors:  S Egawa; M Ohori; T Uchida; S Mashimo; S Kuwao
Journal:  Br J Urol       Date:  1994-10

3.  High-intensity focused ultrasound (HIFU) in prostate cancer: a single centre experience in patients with low, intermediate or high-risk of progression.

Authors:  Andrea Callea; Roberto Piccinni; Vito Zizzi; Domenico Sblendorio; Bartolomeo Berardi; Antonio Tempesta; Francesco Giuseppe Gala; Antonio Traficante
Journal:  Arch Ital Urol Androl       Date:  2010-12

Review 4.  MR imaging and MR spectroscopy in prostate cancer management.

Authors:  Sharyn Katz; Mark Rosen
Journal:  Radiol Clin North Am       Date:  2006-09       Impact factor: 2.303

Review 5.  1H magnetic resonance spectroscopy of prostate cancer: biomarkers for tumor characterization.

Authors:  Kristen L Zakian; Amita Shukla-Dave; Ellen Ackerstaff; Hedvig Hricak; Jason A Koutcher
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

6.  Citrate versus heparin anticoagulation in chronic haemodialysis patients.

Authors:  M J Janssen; P C Huijgens; A A Bouman; P L Oe; A J Donker; J van der Meulen
Journal:  Nephrol Dial Transplant       Date:  1993       Impact factor: 5.992

7.  Prostatic carcinoma: staging with MR imaging at 1.5 T.

Authors:  M Bezzi; H Y Kressel; K S Allen; M L Schiebler; H G Altman; A J Wein; H M Pollack
Journal:  Radiology       Date:  1988-11       Impact factor: 11.105

8.  Prostate cancer: relationships between postbiopsy hemorrhage and tumor detectability at MR diagnosis.

Authors:  Tsutomu Tamada; Teruki Sone; Yoshimasa Jo; Akira Yamamoto; Takenori Yamashita; Naoto Egashira; Shigeki Imai; Masao Fukunaga
Journal:  Radiology       Date:  2008-06-06       Impact factor: 11.105

9.  Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images.

Authors:  S White; H Hricak; R Forstner; J Kurhanewicz; D B Vigneron; C J Zaloudek; J M Weiss; P Narayan; P R Carroll
Journal:  Radiology       Date:  1995-05       Impact factor: 11.105

10.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values.

Authors:  D W Keetch; W J Catalona; D S Smith
Journal:  J Urol       Date:  1994-06       Impact factor: 7.450

View more
  14 in total

Review 1.  Prostate cancer detection and diagnosis: the role of MR and its comparison with other diagnostic modalities--a radiologist's perspective.

Authors:  Tobias Penzkofer; Clare M Tempany-Afdhal
Journal:  NMR Biomed       Date:  2013-09-03       Impact factor: 4.044

2.  Multiparametric MR imaging of peripheral zone prostate cancer: effect of postbiopsy hemorrhage on cancer detection according to Gleason score and tumour volume.

Authors:  Sung Il Jung; Hae Jeong Jeon; Hee Sun Park; Mi Hye Yu; Young Jun Kim; Seung Eun Lee; So Dug Lim
Journal:  Br J Radiol       Date:  2018-03-09       Impact factor: 3.039

Review 3.  Implementation of Multi-parametric Prostate MRI in Clinical Practice.

Authors:  Andrea S Kierans; Samir S Taneja; Andrew B Rosenkrantz
Journal:  Curr Urol Rep       Date:  2015-08       Impact factor: 3.092

4.  A urologist's perspective on prostate cancer imaging: past, present, and future.

Authors:  Arvin K George; Baris Turkbey; Subin G Valayil; Akhil Muthigi; Francesca Mertan; Michael Kongnyuy; Peter A Pinto
Journal:  Abdom Radiol (NY)       Date:  2016-05

Review 5.  Benign Conditions That Mimic Prostate Carcinoma: MR Imaging Features with Histopathologic Correlation.

Authors:  Yu Xuan Kitzing; Adilson Prando; Celi Varol; Gregory S Karczmar; Fiona Maclean; Aytekin Oto
Journal:  Radiographics       Date:  2015-11-20       Impact factor: 5.333

6.  ECR 2015 Book of Abstracts - D - Satellite Symposia.

Authors: 
Journal:  Insights Imaging       Date:  2015-03

7.  Value of T1/T2-weighted magnetic resonance imaging registration to reduce the postbiopsy hemorrhage effect for prostate cancer localization.

Authors:  Ja Yeon You; Hak Jong Lee; Sung Il Hwang; Yun Jung Bae; Hannah Kim; Helen Hong; Gheeyoung Choe
Journal:  Prostate Int       Date:  2015-07-17

8.  False positive and false negative diagnoses of prostate cancer at multi-parametric prostate MRI in active surveillance.

Authors:  Jeffrey S Quon; Bardia Moosavi; Maneesh Khanna; Trevor A Flood; Christopher S Lim; Nicola Schieda
Journal:  Insights Imaging       Date:  2015-05-23

Review 9.  Benign causes of diffusion restriction foci in the peripheral zone of the prostate: diagnosis and differential diagnosis.

Authors:  Nirjhor M Bhowmik; Jinxing Yu; Ann S Fulcher; Mary A Turner
Journal:  Abdom Radiol (NY)       Date:  2016-05

10.  Detecting prostate cancer and prostatic calcifications using advanced magnetic resonance imaging.

Authors:  Shewei Dou; Yan Bai; Ankit Shandil; Degang Ding; Dapeng Shi; E Mark Haacke; Meiyun Wang
Journal:  Asian J Androl       Date:  2017 Jul-Aug       Impact factor: 3.285

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.